AKT1 and Miyoshi myopathy: Since inhibition of the MEK-dependent branch of MAPK signaling proved ineffective in MM samples (compare Fig. S1), we selected clinically relevant alpelisip (iPI3K) and afuresertib (iAKT) to inhibit PI3K and AKT signaling [30], respectively.